Crystagen vs Prostamax
Moderate Research vs Moderate Research
compatible Part of Khavinson bioregulator family; targets different tissue.
Molecular Data
Crystagen Prostamax
Weight 359 Da 473 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes Not established
Chain 3 amino acids 4 amino acids
Type Tripeptide bioregulator Tetrapeptide bioregulator
Key Benefits
Crystagen
01 Normalizes immune function in 82% of patients
02 Stimulates normal lymphocyte proliferation
03 Inhibits tumor cell growth (antitumor activity)
04 Doubles HSP gene expression (stress resistance)
05 Reduces respiratory viral infections
06 Activates B-cell immune system
07 Normalizes IL-6 expression
08 Effective after radiation/chemotherapy
Prostamax
01 Reduces prostate inflammation
02 Decreases prostatic swelling
03 Reduces vascular congestion (hyperemia)
04 Decreases immune cell infiltration
05 Reduces scarring in prostate tissue
06 Promotes chromatin decondensation
07 Reactivates age-repressed genes
08 Improves lymphocyte function
Dosing Protocols
Crystagen
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Prostamax
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10-15 days
Side Effects
Crystagen
Generally well-tolerated
Minimal side effects reported
Prostamax
Generally well-tolerated
Minimal side effects reported
Contraindications
Active autoimmune flares (consult physician)
Known hypersensitivity
Pregnancy or breastfeeding
Prostate cancer (consult oncologist)
Known hypersensitivity
Pregnancy (not applicable)
Research Evidence
Crystagen Prostamax
Status Moderate Research Moderate Research
References 4 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.